Low-molecular-pounds heparin , at a dose of 100 U per kilogram of body weight twice daily, and warfarin, at a dosage adjusted to accomplish a therapeutic worldwide normalized ratio of 2.0 to 3.0, were administered, and no recurrent thrombosis provides appeared throughout a 14-month follow-up period. No grouped relative had a brief history of venous thrombosis. Methods Coagulation Assays We performed coagulation lab tests and assessed the patient for thrombophilia as described previously.7,8 Activity degrees of factor IX were measured by means of a one-stage clotting assay by using the reagent Actin , and aspect IX antigen levels were determined with the use of matched-set polyclonal antibodies .Bloodstream samples for antibody examining were attained on day 0, day 21 , day 31, and day 42. With a list of feasible adverse events and digital thermometers provided by the investigator, subjects documented daily oral temperature and injection-site and systemic adverse events through day 42, using a grading scale based on interference with normal daily activities. On days 3, 10, 21, 24, 31, and 42, subjects came back to the clinic for inspection of the injection site and evaluation of adverse events. Blood specimens for scientific laboratory evaluation were acquired at the screening go to and on times 10, 31, and 42.